North America Alopecia Treatment (Hair Loss) Market – Industry Trends and Forecast to 2030

North America Alopecia Treatment (Hair Loss) Market Analysis and Size         

Alopecia is a term that refers to hair loss caused by specific medical illnesses or nutritional disorders. Hair loss is becoming more common as a result of sedentary lifestyles and unhealthy eating habits. Furthermore, hair loss is caused by ageing and hormonal imbalance and an increase in chronic diseases including arthritis, cancer, hypertension, and depression, particularly among the middle-aged population. As per the American Hair Loss Association, androgenetic alopecia accounts for almost 95 percent of hair loss in men. Over 800,000 people worldwide are looking for a solution to their hair loss.

Data Bridge Market Research analyzes that the alopecia treatment (hair loss) market which was USD 1,947.87 million in 2022, would reach up to USD 3,081.26 million by 2030, and is expected to undergo a CAGR of 5.90% during the forecast period. “Minoxidil” accounts for the largest market share in drug type segment in the alopecia treatment (hair loss) market due to the benefits it offers in treatment of hair loss. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Alopecia is an autoimmune skin condition that affects the growth of healthy hair follicles on the scalp, face, and other parts of the body. The type of alopecia areata, the patient's age, and the extent of hair loss all influence treatment. Alopecia treatment focuses on inhibiting the immune system from attacking the hair and encouraging it to regrow. Finasteride, minoxidil and cyclosporine are the alopecia treatment (hair loss) drugs which are indicated for alopecia treatment. Phototherapy, also known as low light laser therapy (LLLT), is gaining popularity around the world since it is less invasive and safer than other therapies.

North America Alopecia Treatment (Hair Loss) Market Dynamics

Drivers

• Increasing prevalence of hair loss

The rising prevalence of hair loss is estimated to enhance the growth of the alopecia treatment (hair loss) market. In 2018, the American Academy of Dermatology Association (AAD) projected that about 50 million men and 30 million women in the United States were plagued with alopecia. According to the Journal of Clinical and Diagnostic Research (JCDR), around 60% of the population suffers from hair thinning, with pattern hair loss being the most common kind of hair loss in both men and women. Furthermore, roughly 2% of the entire population, regardless of gender, is at risk of acquiring alopecia treatment (hair loss) in their lifetime.

• Advancements in treatment technologies

Advancements in alopecia treatment technologies, such as the development of novel medications, surgical procedures like hair transplantation, and innovative therapies like platelet-rich plasma (PRP) treatments, are key drivers of market growth. These advancements offer patients a diverse range of effective and tailored solutions, contributing to increased demand for alopecia treatments. As the field continues to evolve, patients are likely to benefit from a growing array of options that are both technologically advanced and less invasive, thereby fueling the expansion of the alopecia treatment market in North America.

Opportunities

• Innovation in treatment modalities

The growth of the alopecia treatment market spurs innovation in pharmaceuticals, surgery, and therapies. Research and development efforts focus on creating advanced medications, surgical techniques, and therapies such as regenerative medicine to provide patients with more effective and tailored solutions, driving continuous evolution in the field.

• Rise in cosmetic procedures and clinics

The expanding alopecia treatment market offers a growth opportunity for cosmetic clinics. Entrepreneurs can establish specialized clinics offering a range of services, including advanced surgical interventions and non-surgical treatments. This trend not only caters to the rising demand for aesthetic solutions but also creates a niche for clinics dedicated to addressing hair-related concerns.

Restraints/Challenges

• High treatment costs

The high costs associated with certain alopecia treatments, such as hair transplantation or cutting-edge therapies, pose a significant barrier to accessibility. Affordability concerns may limit the adoption of these treatments, prompting a need for cost-effective alternatives and strategies to improve financial access for a broader patient demographic.

• Adverse side effects

Potential side effects associated with alopecia treatments can deter patients from pursuing interventions. Balancing the benefits and risks becomes crucial, and addressing concerns related to adverse effects requires transparent communication between healthcare providers and patients. Minimizing side effects through ongoing research and development is essential for enhancing the safety profile of alopecia treatments.

This alopecia treatment (hair loss) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the alopecia treatment (hair loss) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In August 2021, Pfizer had announced the positive top-line results from phase 2b/3 trial of ritlecitinib in alopecia treatment (hair loss). Ritlecitinib is the first of a new class of covalent kinase inhibitors that target Janus kinase 3 (JAK3) and members of the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family with great selectivity. Ritlecitinib has been found in lab experiments to prevent the function of signaling molecules and immune cells that are thought to contribute to hair loss in persons with alopecia treatment (hair loss)

North America Alopecia Treatment (Hair Loss) Market Scope

The alopecia treatment (hair loss) market is segmented on the basis of drug type, indication, diagnosis, gender, route of administration, end users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Type

• Minoxidil
• Finasteride
• Others

Indication

• Androgenic Alopecia
• Alopecia Areata
• Alopecia Totalis
• Others

Diagnosis

• Trichoscopy
• Skin Biopsy
• Others

Gender

• Male
• Female

Route of Administration

• Oral
• Topical
• Parenteral
• Others

End Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

North America Alopecia Treatment (Hair Loss) Market Regional Analysis/Insights

The alopecia treatment (hair loss) market is analysed and market size insights and trends are provided by country, drug type, indication, diagnosis, gender, route of administration, end users, and distribution channel as referenced above.

The countries covered in the alopecia treatment (hair loss) market report are U.S., Canada and Mexico.

U.S. is expected to dominate the alopecia treatment (hair loss) market with highest market share and growth rate in the forecast period because of the increasing prevalence of male alopecia and advancements in cosmetic procedures for its treatment.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The alopecia treatment (hair loss) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for alopecia treatment (hair loss) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the alopecia treatment (hair loss) market. The data is available for historic period 2010-2020.

Competitive Landscape and North America Alopecia Treatment (Hair Loss) Market Share Analysis

The alopecia treatment (hair loss) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to alopecia treatment (hair loss) market.

Some of the major players operating in the alopecia treatment (hair loss) market are:

• Johnson & Johnson Private Limited (U.S.)
• GlaxoSmithKline plc (UK)
• Merck & Co., Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Cipla Inc. (U.S.)
• Endo International plc (Ireland)
• Zydus Cadila (India)
• Abbott (U.S.)
• Aurobindo Pharma (India)
• Dr. Reddy’s Laboratories Ltd. (India)
• Perrigo Company plc (Ireland)
• Curallux, LLC. (U.S.)
• DR. KURT WOLFF GMBH & CO. KG (Germany)
• WOCKHARDT (India)

SKU-57065